Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016

Date: December 30, 2016
Pages: 1321
Price:
US$ 2,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G49699B5CD9EN
Leaflet:

Download PDF Leaflet

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) – Pipeline Review, H2 2016, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape.

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor. GBMs arise from glial cells, which are cells that form the tissue that surrounds and protects other nerve cells found within the brain and spinal cord. GBMs are mainly composed of star-shaped glial cells known as astrocytes. Signs and symptoms include slowly progressive neurologic deficit, usually motor weakness, headache, generalized symptoms of increased intracranial pressure, including headaches, nausea and vomiting, and cognitive impairment and seizures. Treatment includes radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glioblastoma Multiforme (GBM) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glioblastoma Multiforme (GBM) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 11, 98, 53, 1, 4, 147, 18 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 8, 12, 1, 35 and 8 molecules, respectively.

Glioblastoma Multiforme (GBM) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Glioblastoma Multiforme (GBM) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Glioblastoma Multiforme (GBM) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Glioblastoma Multiforme (GBM) Overview
Therapeutics Development
Glioblastoma Multiforme (GBM) - Therapeutics under Development by Companies
Glioblastoma Multiforme (GBM) - Therapeutics under Investigation by Universities/Institutes
Glioblastoma Multiforme (GBM) - Pipeline Products Glance
Glioblastoma Multiforme (GBM) - Products under Development by Companies
Glioblastoma Multiforme (GBM) - Products under Investigation by Universities/Institutes
Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development
Glioblastoma Multiforme (GBM) - Therapeutics Assessment
Drug Profiles
Glioblastoma Multiforme (GBM) - Dormant Projects 1242
Glioblastoma Multiforme (GBM) - Discontinued Products 1259
Glioblastoma Multiforme (GBM) - Product Development Milestones 1262
Appendix 1278

LIST OF FIGURES

Number of Products under Development for Glioblastoma Multiforme (GBM), H2 2016
Number of Products under Development for Glioblastoma Multiforme (GBM) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

Global Markets Direct's, 'Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2014', provides an overview of the GBM therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for GBM, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

It also reviews key players involved in the therapeutic development for GBM and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

The material was prepared in November, 2014.

LIST OF TABLES

Number of Products under Development for Glioblastoma Multiforme (GBM), H2 2016
Number of Products under Development for Glioblastoma Multiforme (GBM) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Development by Companies, H2 2016 (Contd..7)
Number of Products under Development by Companies, H2 2016 (Contd..8)
Number of Products under Development by Companies, H2 2016 (Contd..9)
Number of Products under Development by Companies, H2 2016 (Contd..10)
Number of Products under Development by Companies, H2 2016 (Contd..11)
Number of Products under Development by Companies, H2 2016 (Contd..12)
Number of Products under Development by Companies, H2 2016 (Contd..13)
Number of Products under Development by Companies, H2 2016 (Contd..14)
Number of Products under Development by Companies, H2 2016 (Contd..15)
Number of Products under Development by Companies, H2 2016 (Contd..16)
Number of Products under Investigation by Universities/Institutes, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Development by Companies, H2 2016 (Contd..10)
Products under Development by Companies, H2 2016 (Contd..11)
Products under Development by Companies, H2 2016 (Contd..12)
Products under Development by Companies, H2 2016 (Contd..13)
Products under Development by Companies, H2 2016 (Contd..14)
Products under Development by Companies, H2 2016 (Contd..15)
Products under Development by Companies, H2 2016 (Contd..16)
Products under Development by Companies, H2 2016 (Contd..17)
Products under Development by Companies, H2 2016 (Contd..18)
Products under Development by Companies, H2 2016 (Contd..19)
Products under Development by Companies, H2 2016 (Contd..20)
Products under Development by Companies, H2 2016 (Contd..21)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
Glioblastoma Multiforme (GBM) - Pipeline by AbbVie Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Activartis Biotech GmbH, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Advanced Accelerator Applications SA, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Advantagene Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Advenchen Laboratories LLC, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Affimed GmbH, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Agenus Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Amal Therapeutics SA, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Ambrx Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Amgen Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Ampio Pharmaceuticals Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by AngioChem Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Apac Biotech Pvt Ltd, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Apceth GmbH & Co KG, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by APIM Therapeutics AS, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Apogenix GmbH, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Ariad Pharmaceuticals Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Arog Pharmaceuticals Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Astellas Pharma Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by AstraZeneca Plc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Athenex Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Axelar AB, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Basilea Pharmaceutica Ltd, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Batu Biologics Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Bayer AG, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by BeiGene Ltd, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Bexion Pharmaceuticals LLC, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Bio-Path Holdings Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Bioasis Technologies Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by BioCancell Ltd, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Biomar Microbial Technologies, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Bioncotech Therapeutics SL, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Biovista Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Boston Biomedical Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Bristol-Myers Squibb Company, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by BTG Plc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Cantex Pharmaceuticals Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Cavion LLC, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Celgene Corp, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Cell Medica Ltd, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Celldex Therapeutics Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Celsion Corp, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by ChemoCentryx Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by CLL Pharma SA, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Coherus BioSciences Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Cortice Biosciences Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Critical Outcome Technologies Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by CTI BioPharma Corp, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Curadev Pharma Pvt Ltd, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Cynata Therapeutics Limited, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by CytoVac A/S, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by CytRx Corp, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Deciphera Pharmaceuticals LLC, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by DEKK-TEC Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by DelMar Pharmaceuticals Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Diffusion Pharmaceuticals Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Ecrins Therapeutics SAS, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by EirGenix Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Eisai Co Ltd, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Eli Lilly and Company, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by EnGeneIC Ltd, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by EntreChem SL, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by ERC Belgium SA, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Evotec AG, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by FirstString Research Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Five Prime Therapeutics Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Gene Techno Science Co Ltd, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Genentech Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Genisphere Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Genor BioPharma Co Ltd, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Genzyme Corp, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by GlaxoSmithKline Plc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by GtreeBNT Co Ltd, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by GW Pharmaceuticals Plc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Hamlet Pharma AB, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Hutchison MediPharma Ltd, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Immatics Biotechnologies GmbH, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Immune Pharmaceuticals Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by ImmunoCellular Therapeutics Ltd, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Immunomedics Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Immunomet Therapeutics Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Immunomic Therapeutics Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Immupharma Plc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Incuron LLC, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Incyte Corp, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Infinity Pharmaceuticals Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Inspyr Therapeutics Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by INSYS Therapeutics Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Intica Biomedical Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Johnson & Johnson, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Kadmon Corp LLC, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Kalgene Pharmaceuticals Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by KaloBios Pharmaceuticals Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Karyopharm Therapeutics Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Kite Pharma Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Komipharm International Co Ltd, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Lentigen Technology Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Les Laboratoires Servier SAS, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by LinXis BV, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Lion Biotechnologies Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Lixte Biotechnology Holdings Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Loxo Oncology, Inc., H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Mabion SA, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by MacroGenics Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Mateon Therapeutics Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Medicenna Therapeutics Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by MedImmune LLC, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Merck & Co Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Merck KGaA, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Midatech Pharma Plc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by MimiVax LLC, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Moleculin Biotech Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Mycenax Biotech Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Nanomerics Ltd, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Neonc Technologies Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Nerviano Medical Sciences Srl, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Neumedicines Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Neuralstem Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by NewLink Genetics Corp, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Northwest Biotherapeutics Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Novartis AG, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Novogen Ltd, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Noxxon Pharma AG, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Nuo Therapeutics Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by NuvOx Pharma LLC, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Omniox Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Oncobiologics Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Oncodesign SA, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Onconova Therapeutics Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Oncternal Therapeutics Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Orphagen Pharmaceuticals Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Orphit SAS, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Oryx GmbH & Co KG, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Peloton Therapeutics Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Peregrine Pharmaceuticals Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Pfizer Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by PharmAbcine Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by PharmaCyte Biotech Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Pharmicell Co Ltd, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by PIQUR Therapeutics AG, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Plex Pharmaceuticals Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Plexxikon Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Prana Biotechnology Ltd, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Progenics Pharmaceuticals Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Puma Biotechnology Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Recepta Biopharma SA, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Regulus Therapeutics Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by ReNeuron Group Plc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Rexahn Pharmaceuticals Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Rgenix Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Richter Gedeon Nyrt, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Rigontec GmbH, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Sanofi, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Sapience Therapeutics Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Scancell Holdings Plc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Sellas Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Sigma-Tau SpA, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by SignPath Pharma Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by SOM Biotech SL, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Sorrento Therapeutics Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by StemGen SpA, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Stemline Therapeutics Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Susavion Biosciences Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Symphogen A/S, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Terpenoid Therapeutics Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Therapeia GmbH & Co KG, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Theravectys SA, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Threshold Pharmaceuticals Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Tocagen Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by TRACON Pharmaceuticals Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Transgene SA, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Trillium Therapeutics Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by TVAX Biomedical Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Tyme Technologies Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Upsher-Smith Laboratories Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Vascular Biogenics Ltd, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Vault Pharma Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Vaximm AG, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by VBI Vaccines Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by VCN Biosciences SL, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Vertex Pharmaceuticals Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by ViraTherapeutics GmbH, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Virttu Biologics Ltd, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by Vyriad Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by X4 Pharmaceuticals Inc, H2 2016
Glioblastoma Multiforme (GBM) - Pipeline by ZIOPHARM Oncology Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2016 1284
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..1), H2 2016 1285
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..2), H2 2016 1286
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..3), H2 2016 1287
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..4), H2 2016 1288
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..5), H2 2016 1289
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..6), H2 2016 1290
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..7), H2 2016 1291
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..8), H2 2016 1292
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..9), H2 2016 1293
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..10), H2 2016 1294
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..11), H2 2016 1295
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..12), H2 2016 1296
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..13), H2 2016 1297
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..14), H2 2016 1298
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..15), H2 2016 1299
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..16), H2 2016 1300
Glioblastoma Multiforme (GBM) - Discontinued Products, H2 2016 1301
Glioblastoma Multiforme (GBM) - Discontinued Products (Contd..1), H2 2016 1302
Glioblastoma Multiforme (GBM) - Discontinued Products (Contd..2), H2 2016 1303

Skip to top


Ask Your Question

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: